Redefining the Role of Cardiologists in the Management of Type 2 Diabetes: Best Practices for Cardiovascular Risk Reduction




Diabetes was once thought of as a disease of elevated blood glucose. The opportunity for cardiovascular disease (CVD) prevention in patients with Type 2 Diabetes Mellitus (T2DM) has recently expanded.  Despite major therapeutic advances leading to improved outcomes over the past 2 decades, CVD remains the leading cause of morbidity and mortality in patients with TD2M. Certain sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have shown significant reductions in the risk of major adverse cardiovascular events (MACE). The arrival of these new agents proven to reduce adverse CV outcomes in patients with T2DM has triggered a major paradigm shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction. Lowering the risk of CV-related death in T2DM patients can no longer be ignored. This curriculum is meant to serve as a call to action for cardiologists to reevaluate and reengage in the management of T2DM patients with CV risk.



Silvio E. Inzucchi, MD
Professor of Medicine
Medical Director, Yale Diabetes Center
Yale School of Medicine
New Haven, Connecticut

Mikhail Kosiborod, MD, FACC, FAHA
Professor of Medicine
Saint Luke’s Mid America Heart Institute
University of Missouri-Kansas City
Kansas City, Missouri


Release date: December 13, 2019
Expiration date: December 13, 2020
Estimated time to complete activity: 30 minutes



This multi-supported educational program is designed to meet the educational needs of cardiologists, specialty nurse practitioners (NPs), and specialty physician assistants (PAs) interested in the treatment of T2DM in patients with or at risk for developing CVD.

  • Portray the burdens associated with CVD in patients with T2DM
  • Integrate data from CV outcome trials into the management of patients with T2DM to improve CV outcomes
  • Examine recently updated clinical guidelines including the 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
  • Incorporate effective multidisciplinary care strategies into clinical practice to ensure a continuum of care for patients with T2DM

There are no fees for participating and receiving CME credit for this activity.  During the period of December 13, 2019 through December 13, 2020 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits(s)TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or


Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity.  All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/ planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Silvio Inzucchi, MD
Consultant: Abbott/Alere, AstraZeneca, Boehringer Ingelheim, Eisai (TIMI), Merck, Novo Nordisk, Sanofi/Lexicon, VTV Therapeutics, Zafgen

Mikhail Kosiborod, MD, FACC, FAHA
Research Grant: AstraZeneca, Boehringer Ingelheim
Consultant/Advisory Board: Amarin, Amgen, Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Eisai, Eli Lilly, GlaxoSmithKline, Glytec, Intarcia, Janssen, Merck (Diabetes), Novartis, Novo Nordisk, Sanofi
Speaker: AstraZeneca, Boehringer Ingelheim, Novo Nordisk

Integrity Continuing Education, Inc. Planners/managers do not have any conflicts of interest to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  Integrity Continuing Education, Inc. and AstraZeneca Pharmaceuticals LP and Novo Nordisk do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity provided by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliations(s), street address, telephone number, fax number, and… (continued).


Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.


The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgement of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Provided by Integrity Continuing Education, Inc.


Supported by an educational grant from AstraZeneca Pharmaceuticals, LP and Novo Nordisk.


Continue to Pretest